Maze Therapeutics, Inc. SEC filings MAZE

Maze Therapeutics, Inc. has 222 filings in SEC EDGAR's recent list, going back to Jun 21, 2024. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.

Form Description Filed Period
POS AM Filing May 12, 2026 —
424B5 Prospectus supplement Apr 22, 2026 —
S-8 Employee stock plan registration Feb 4, 2026 —
S-3ASR Automatic shelf registration Feb 4, 2026 —
424B3 Prospectus Nov 6, 2025 —
S-1 Registration statement Oct 17, 2025 —
S-8 Employee stock plan registration Jan 31, 2025 —
424B4 Prospectus Jan 31, 2025 —
S-1MEF Filing Jan 30, 2025 —
S-1/A Amended registration statement Jan 30, 2025 —
S-1/A Amended registration statement Jan 27, 2025 —
S-1 Registration statement Jan 7, 2025 —

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MAZE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1842295

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.